• Chakshu Walia
• Komal Mehra

Etoricoxib (Arcoxia) is a cyclooxygenase-2 (COX-2) selective inhibitor, particular enzyme which involved in severe inflammation and pain. It comes under the class of nonsteroidal anti-inflammatory drug (NSAIDs) of the COX-2-selective inhibitors(coxibs). As, the etoricoxib recommended dosage for osteoarthritis is 60 mg/day, for rheumatoid arthritis is 90 mg/day and for acute gouty arthritis is 120 mg/day. In patients with rheumatoid arthritis, improvements in tender and swollen joint counts and patient and investigator global assessment of disease activity were significantly greater in etoricoxib than in placebo recipients in two studies. Etoricoxib was also significantly more effective than naproxen in one of these studies. This review provides an update regarding the etoricoxib medical uses, action of this drug, solubility and various adverse effects

Etoricoxib, History, working, solubility, mechanism, toxicity, Adverse effects.

"Review on Dose, Destination and delivery aspects of Etoricoxib", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 7, page no.e640-e649, July-2023, Available :http://www.jetir.org/papers/JETIR2307468.pdf

"Review on Dose, Destination and delivery aspects of Etoricoxib", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 7, page no. ppe640-e649, July-2023, Available at : http://www.jetir.org/papers/JETIR2307468.pdf